The 2026 Germany Life Science Trend Analysis, produced in partnership with Bio Deutschland, Bio.NRW, bioRN, BioSaxony, and GTAI, highlights one of Europe’s most established life science markets, with a deep-rooted biotech services infrastructure, a strong therapeutics pipeline, and a broad medtech ecosystem spanning instruments, diagnostics, and implantable devices.
The ecosystem encompasses 4,240 companies in total, including 1,328 biotech firms, 664 medtech companies, 208 digital health companies, and 222 investor companies. Within the biotech segment, R&D services dominates at 858 companies (65%), while therapeutics & diagnostics accounts for 271 firms (20%). The leading therapeutic modalities are small molecules (14%), immunotherapy (11%), and anti-infectives (11%), with antibodies (10%) and molecular diagnostics (7%) also featuring prominently. Oncology leads the clinical pipeline with 506 assets, followed by infectiology/parasitology (107) and neurology (102). Total assets in development span all stages from preclinical through Phase III, with 1,482 assets available for out-licensing, of which 639 are therapeutics — the majority at preclinical stage (276).
The ownership landscape is predominantly private and independent across all sectors, with pharma standing as the notable exception at only 57% private versus 38% subsidiaries, reflecting the presence of large international groups with German operations. Company formation peaked in 2017 (81 companies) and 2019 (77 companies), with a visible contraction through 2022–2024 and only 17 companies recorded in 2024 — consistent with a global slowdown in life science incorporations during this period.
Financing activity reflects a volatile but recovering market. Private equity rounds for life science companies totalled $1,167M in 2024, declining to $823M in 2025, though biotech-specific funding showed relative resilience at $727M and $645M respectively. The five-year dataset reveals a strong peak in 2021 H2 ($511M across 12 rounds), a prolonged trough through 2022–2023, and a notable single-half surge in 2025 H2 ($585M across 11 rounds). The top 2025 private equity rounds were led by Tubulis GmbH ($361M Series C), AMBOSS GmbH ($252M), and Ortivity ($200M). On the M&A front, Germany’s most significant 2025 deal was BioNTech’s acquisition of CureVac SE for $1,250M, followed by Daiichi Sankyo’s asset acquisition of Glycotope GmbH ($132.5M) and GSK’s full acquisition of CELLphenomics ($45.5M), underscoring continued international interest in German biotech assets particularly in oncology and RNA-based modalities.
Looking ahead, the German life science sector is supported by a broad out-licensing pipeline, a dominant R&D services infrastructure, and signs of recovering venture momentum in the second half of 2025 — positioning it as a cornerstone of the European life science ecosystem, with continued strength across therapeutics, medtech, and translational research.
For more detailed insights, request a free Biotechgate demo.
Download the Germany Trend Analysis 2026 for the full PDF.